Company

Panolos Bioscience Co., Ltd.

Panolos Bioscience develops biopharmaceutical drug candidates for cancer and rare diseases.

About

Panolos Bioscience uses its aART platform to develop protein structure-based drugs. Its oncology pipeline includes PB101 and other drug candidates. Founded in 2019 by CEO Hyeseong Lim, the company is based in South Korea. It raised KRW 20 billion in Series A funding in May 2021.

1Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in